Cooperative Agreement U01FD004963

Dynocardia Inc. received a $256,000 National Science Foundation Project Grant to advance development of a novel continuous, cuffless blood pressure monitoring device. Funded through the NSF Engineering Directorate's SBIR program, the award will support Dynocardia's efforts to address motion artifacts and enable accurate, beat-to-beat blood pressure measurements in hospital intensive care and operating room settings. Accurate 24-hour blood pressure monitoring has potential to significantly...

The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $499,881 to Dynocardia, Inc. to complete the verification and validation (V&V) of their production-grade Vitrack hospital device for continuous, non-invasive blood pressure monitoring. Vitrack is a wrist-wearable device that utilizes proprietary optomechanical sensors and computer vision technology to accurately measure...

The federal Project Grant award R56HL175516, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The $834,249 award will fund a longitudinal study of approximately 1,800 patients (900 transcatheter, 900 surgical) to evaluate long-term...

This $7,836,599.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support the development of a novel centrifugal left ventricular assist device (LVAD) with wireless power transfer and anti-thrombotic coating technology. The prime awardee, Georgia Tech Research Corporation, will lead the research and development efforts, which include fabricating and characterizing slippery hydrophilic (SLIC) coatings to improve...

The National Center on Birth Defects and Developmental Disabilities, part of the Centers for Disease Control and Prevention (CDC), awarded a $998,912 Cooperative Agreement to Duke University to establish the North Carolina Congenital Heart Disease Surveillance Network. This 5-year award, funded under the Disabilities Prevention program (CFDA 93.184), supports non-research activities focused on developing, implementing, evaluating, and disseminating health promotion strategies to reduce health...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $677,635 to the University of Southern California (USC) to develop a novel high-speed 4D echocardiography system with adjustable multi-planar acquisition capabilities. The project aims to advance 4D transthoracic echocardiography (TTE) by creating broadband echocardiography transducers that utilize a matrix array periphery to enable...

This $702,534 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by the Texas A&M Engineering Experiment Station (Tees) to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology. The goal is to segregate and quantify the independent contributions of passive and active remodeling events to impaired left ventricular relaxation (ILVR), a key...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $375,750 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to The General Hospital Corporation, doing business as Massachusetts General Hospital, to develop and validate a multi-wavelength wearable edema and microcirculation monitor for detecting decompensation in cardiac failure patients. The project aims to build upon the organization's previously...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,283,558.00 to the Massachusetts Institute of Technology (MIT) to develop and evaluate a novel "Multi-Electroplasmonic Nanoantenna Arrays" (MENAS) technology. The MENAS system aims to enable wireless, high-resolution recording of cardiomyocyte action potentials, which is critical for advancing research on cardiac arrhythmias...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $293,653 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to 3DT Holdings, LLC, a minority-owned biomedical engineering company. The funding will support the development of a software tool to optimize cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) for heart failure patients with left bundle branch block and ischemia. The project...